190 related articles for article (PubMed ID: 15783085)
1. MHC class I down regulation, tumour escape from immune surveillance and design of therapeutic strategies.
Bubeník J
Folia Biol (Praha); 2005; 51(1):1-2. PubMed ID: 15783085
[No Abstract] [Full Text] [Related]
2. MHC class I down-regulation: tumour escape from immune surveillance? (review).
Bubeník J
Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
[TBL] [Abstract][Full Text] [Related]
3. MHC class I antigens and immune surveillance in transformed cells.
Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
[TBL] [Abstract][Full Text] [Related]
4. T lymphocyte-derived TNF and IFN-γ repress HFE expression in cancer cells.
Reuben A; Godin-Ethier J; Santos MM; Lapointe R
Mol Immunol; 2015 Jun; 65(2):259-66. PubMed ID: 25700349
[TBL] [Abstract][Full Text] [Related]
5. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
Burr ML; Sparbier CE; Chan KL; Chan YC; Kersbergen A; Lam EYN; Azidis-Yates E; Vassiliadis D; Bell CC; Gilan O; Jackson S; Tan L; Wong SQ; Hollizeck S; Michalak EM; Siddle HV; McCabe MT; Prinjha RK; Guerra GR; Solomon BJ; Sandhu S; Dawson SJ; Beavis PA; Tothill RW; Cullinane C; Lehner PJ; Sutherland KD; Dawson MA
Cancer Cell; 2019 Oct; 36(4):385-401.e8. PubMed ID: 31564637
[TBL] [Abstract][Full Text] [Related]
6. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
Kriegsman BA; Vangala P; Chen BJ; Meraner P; Brass AL; Garber M; Rock KL
J Immunol; 2019 Oct; 203(7):1999-2010. PubMed ID: 31471524
[TBL] [Abstract][Full Text] [Related]
7. The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects.
Oliveira CC; van Veelen PA; Querido B; de Ru A; Sluijter M; Laban S; Drijfhout JW; van der Burg SH; Offringa R; van Hall T
J Exp Med; 2010 Jan; 207(1):207-21. PubMed ID: 20038604
[TBL] [Abstract][Full Text] [Related]
8. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
Shklovskaya E; Rizos H
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201655
[TBL] [Abstract][Full Text] [Related]
9. [Towards a holistic vision of cancer].
Solary É; Laplane L
Med Sci (Paris); 2016 Apr; 32(4):315-6. PubMed ID: 27137681
[No Abstract] [Full Text] [Related]
10. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
11. Replicative senescence of CD8 T cells: potential effects on cancer immune surveillance and immunotherapy.
Effros RB
Cancer Immunol Immunother; 2004 Oct; 53(10):925-33. PubMed ID: 15067431
[TBL] [Abstract][Full Text] [Related]
12. How tumors escape immune destruction and what we can do about it.
Gilboa E
Cancer Immunol Immunother; 1999 Oct; 48(7):382-5. PubMed ID: 10501851
[TBL] [Abstract][Full Text] [Related]
13. Xenopus, a unique comparative model to explore the role of certain heat shock proteins and non-classical MHC class Ib gene products in immune surveillance.
Robert J; Goyos A; Nedelkovska H
Immunol Res; 2009 Dec; 45(2-3):114-22. PubMed ID: 19189057
[TBL] [Abstract][Full Text] [Related]
14. Membrane-bound versus soluble major histocompatibility complex Class I-related chain A and major histocompatibility complex Class I-related chain B differential expression: Mechanisms of tumor eradication versus evasion and current drug development strategies.
Suresh PK
J Cancer Res Ther; 2016; 12(4):1224-1233. PubMed ID: 28169232
[TBL] [Abstract][Full Text] [Related]
15. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
[TBL] [Abstract][Full Text] [Related]
16. From tumor cell metabolism to tumor immune escape.
Villalba M; Rathore MG; Lopez-Royuela N; Krzywinska E; Garaude J; Allende-Vega N
Int J Biochem Cell Biol; 2013 Jan; 45(1):106-13. PubMed ID: 22568930
[TBL] [Abstract][Full Text] [Related]
17. Playing hide and seek: Tumor cells in control of MHC class I antigen presentation.
Jongsma MLM; Neefjes J; Spaapen RM
Mol Immunol; 2021 Aug; 136():36-44. PubMed ID: 34082257
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunoediting from immune surveillance to immune escape.
Kim R; Emi M; Tanabe K
Immunology; 2007 May; 121(1):1-14. PubMed ID: 17386080
[TBL] [Abstract][Full Text] [Related]
19. Escape from immune- and nonimmune-mediated tumor surveillance.
Malmberg KJ; Ljunggren HG
Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546
[TBL] [Abstract][Full Text] [Related]
20. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
